Press Release: UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
UroGen Pharma Ltd | 10-K/A: Annual report (Amendment)
Express News | Guggenheim Reiterates Buy on UroGen Pharmato Buy
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $55
$URGN Stock Is up 7% Today. Here's What We See in Our Data.
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Trade Tensions Persist
Top Premarket Gainers
UroGen Pharma Price Target Maintained With a $25.00/Share by D. Boral Capital
UroGen Pharma Reports Nearly 4-Year Response for Urothelial Cancer Therapy -- Shares Up Pre-Bell
Reported Sunday, UroGen Highlights Nearly Four-Year Duration Of Response In OLYMPUS Long-Term Follow-Up Study Of JELMYTO
Reported Saturday, UroGen Pharma's UGN-301 Phase 1 Trial Shows Sustained Bladder Exposure And No Dose-Limiting Toxicities In Non-Muscle Invasive Bladder Cancer
UroGen Pharma Announces Encouraging Results From a Phase 1 Dose-Escalation Study Evaluating...
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% From the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
UroGen Pharma Is Maintained at Neutral by Goldman Sachs
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Scotiabank Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $23
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Cuts Target Price to $16